Literature DB >> 26166697

Risk factors for ventilator-associated pneumonia in patients with severe traumatic brain injury in a Serbian trauma centre.

Bojan Jovanovic1, Zoka Milan2, Ljiljana Markovic-Denic3, Olivera Djuric3, Kristina Radinovic4, Krstina Doklestic5, Jelena Velickovic1, Nenad Ivancevic5, Pavle Gregoric5, Milena Pandurovic6, Djordje Bajec7, Vesna Bumbasirevic1.   

Abstract

INTRODUCTION: The aims of this study were (1) to assess the incidence of ventilator-associated pneumonia (VAP) in patients with traumatic brain injury (TBI), (2) to identify risk factors for developing VAP, and (3) to assess the prevalence of the pathogens responsible. PATIENTS AND METHODS: The following data were collected prospectively from patients admitted to a 24-bed intensive care unit (ICU) during 2013/14: the mechanism of injury, trauma distribution by system, the Acute Physiology and Chronic Health Evaluation (APACHE) II score, the Abbreviated Injury Scale (AIS) score, the Injury Severity Score (ISS), underlying diseases, Glasgow Coma Scale (GCS) score, use of vasopressors, need for intubation or cardiopulmonary resuscitation upon admission, and presence of pulmonary contusions. All patients were managed with a standardized protocol if VAP was suspected. The Sequential Organ Failure Assessment (SOFA) score and the Clinical Pulmonary Infection Score (CPIS) were measured on the day of VAP diagnosis.
RESULTS: Of the 144 patients with TBI who underwent mechanical ventilation for >48h, 49.3% did not develop VAP, 24.3% developed early-onset VAP, and 26.4% developed late-onset VAP. Factors independently associated with early-onset VAP included thoracic injury (odds ratio (OR) 8.56, 95% confidence interval (CI) 2.05-35.70; p=0.003), ISS (OR 1.09, 95% CI 1.03-1.15; p=0.002), and coma upon admission (OR 13.40, 95% CI 3.12-57.66; p<0.001). Age (OR 1.04, 95% CI 1.02-1.07; p=0.002), ISS (OR 1.09, 95% CI 1.04-1.13; p<0.001), and coma upon admission (OR 3.84, 95% CI 1.44-10.28; p=0.007) were independently associated with late-onset VAP (Nagelkerke r(2)=0.371, area under the curve (AUC) 0.815, 95% CI 0.733-0.897; p<0.001). The 28-day survival rate was 69% in the non-VAP group, 45.7% in the early-onset VAP group, and 31.6% in the late-onset VAP group. Acinetobacter spp was the most common pathogen in patients with early- and late-onset VAP.
CONCLUSIONS: These results suggest that the extent of TBI and trauma of other organs influences the development of early VAP, while the extent of TBI and age influences the development of late VAP. Patients with early- and late-onset VAP harboured the same pathogens.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Injury; Neurotrauma; Pneumonia; Predictors

Mesh:

Year:  2015        PMID: 26166697     DOI: 10.1016/j.ijid.2015.07.005

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  12 in total

1.  Risk factors for ventilator-associated pneumonia in trauma patients: A descriptive analysis.

Authors:  Suresh Kumar Arumugam; Insolvisagan Mudali; Gustav Strandvik; Ayman El-Menyar; Ammar Al-Hassani; Hassan Al-Thani
Journal:  World J Emerg Med       Date:  2018

2.  Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals.

Authors:  D Delle Rose; P Pezzotti; E Fortunato; P Sordillo; S Gini; S Boros; M Meledandri; M T Gallo; G Prignano; R Caccese; M D'Ambrosio; G Citterio; M Rocco; F Leonardis; S Natoli; C Fontana; M Favaro; M G Celeste; T Franci; G P Testore; M Andreoni; L Sarmati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-06       Impact factor: 3.267

Review 3.  THE GLYCOCALYX AND TRAUMA: A REVIEW.

Authors:  Andreia Z Chignalia; Feliz Yetimakman; Sarah C Christiaans; Sule Unal; Benan Bayrakci; Brant M Wagener; Robert T Russell; Jeffrey D Kerby; Jean-Francois Pittet; Randal O Dull
Journal:  Shock       Date:  2016-04       Impact factor: 3.454

Review 4.  Healthcare-Associated Infections in the Neurocritical Care Unit.

Authors:  Katharina M Busl
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-27       Impact factor: 5.081

5.  Early-Onset Ventilator-Associated Pneumonia in Patients with Severe Traumatic Brain Injury: Incidence, Risk Factors, and Consequences in Cerebral Oxygenation and Outcome.

Authors:  Pierre Esnault; Cédric Nguyen; Julien Bordes; Erwan D'Aranda; Ambroise Montcriol; Claire Contargyris; Jean Cotte; Philippe Goutorbe; Christophe Joubert; Arnaud Dagain; Henry Boret; Eric Meaudre
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

6.  Impact of grouping complications on mortality in traumatic brain injury: A nationwide population-based study.

Authors:  Chung-Han Ho; Fu-Wen Liang; Jhi-Joung Wang; Chung-Ching Chio; Jinn-Rung Kuo
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

Review 7.  Incidence, Risk Factors, and Outcomes of Ventilator-Associated Pneumonia in Traumatic Brain Injury: A Meta-analysis.

Authors:  Yating Li; Chenxia Liu; Wei Xiao; Tiantian Song; Shuhui Wang
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.210

8.  Nutritional Status Disorders and Selected Risk Factors of Ventilator-Associated Pneumonia (VAP) in Patients Treated in the Intensive Care Ward-A Retrospective Study.

Authors:  Lucyna Ścisło; Elżbieta Walewska; Iwona Bodys-Cupak; Agnieszka Gniadek; Maria Kózka
Journal:  Int J Environ Res Public Health       Date:  2022-01-05       Impact factor: 3.390

Review 9.  Brain-lung interactions and mechanical ventilation in patients with isolated brain injury.

Authors:  Mairi Ziaka; Aristomenis Exadaktylos
Journal:  Crit Care       Date:  2021-10-13       Impact factor: 9.097

10.  Prediction of in-hospital mortality in patients with post traumatic brain injury using National Trauma Registry and Machine Learning Approach.

Authors:  Ahmad Abujaber; Adam Fadlalla; Diala Gammoh; Husham Abdelrahman; Monira Mollazehi; Ayman El-Menyar
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2020-05-27       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.